Rakesh Sutariya is the visionary Managing Director and CEO of Zenovel, bringing over 17 years of expertise in strategic marketing, operation management, business development, bio-analytical, clinical, and IT fields. He has successfully monitored, audited, and conducted over 1,000 clinical trials, while
helping design and execute complex studies for regulatory submissions. Under his leadership, Zenovel
has served over 150 global clients across 45 countries, supporting pharmaceutical development through GCP, GMP, and regulatory services. His leadership at Zenovel is marked by his hands-on approach,
overseeing team and collaborating closely with various departments to ensure the company’s growth
and success.
His approach to quality is driven by a commitment to ethical practices and maintaining the highest standards in every aspect of operations. For Mr. Rakesh, “Quality is not just about achieving results—it’s about doing so in a way that aligns with Zenovel’s core values of compassion, wisdom, and excellence”. He believes in empowering his team through continuous learning and development, ensuring they stay at the forefront of industry innovations while maintaining a keen focus on regulatory compliance
Mr. Rakesh’s client approach is proactive and collaborative. He views every client partnership as an extension of Zenovel’s mission to deliver safe, effective, and reliable pharmaceutical solutions. His philosophy centers on providing tailored, cost-effective services, and fostering open communication, ensuring that clients feel supported throughout their journey.
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
Welcome to the Zenovel Blog! We are a leading provider of drug regulatory consulting and education, focusing on advancing pharmaceutical innovation while ensuring safety and compliance. This blog delves into the essentials of Drug Regulatory Affairs (DRA), covering its scope, career opportunities, and intricate processes involved in bringing new drugs
The international pharmaceutical landscape is inherently connected to the global economy and global trade, which is consisted with the quality and safety assurance , well-controlled quality and safety. Compliance with international pharmaceutical standards has changed from an optional step to a requirement. The Pharmaceutical Inspection Co-operation Scheme (PIC/S Certification) is
Lipinski’s Rule of 5 (Ro5) is a crucial guideline in pharmaceutical development, helping researchers evaluate a compound’s likelihood of becoming an effective oral drug. However, with the rapid evolution of therapeutic strategies, it’s worth considering the relevance of Ro5 in the current drug design landscape. Understanding Lipinski’s Rule of 5
Regulatory affairs (RA) play a crucial role in the pharmaceutical industry; ensuring products meet quality, safety, and efficacy. As the industry grow further the need for qualified professionals to bridge gaps between companies and regulators increases. This blog explores Zenovel regulatory affairs expertise, our various facets, and valuable contribution to
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.
